Release Date: May 30, 2025

Expiration Date: May 30, 2026

Activity Overview

Patients with diabetic retinopathy (DR) or diabetic macular edema (DME) tend to have a host of comorbidities and a considerable burden of required treatments and medical appointments. Recent additions to treatment options for DR and DME provide opportunities to reduce patients’ eye-related treatment burden. In this program, expert faculty present illustrative cases of patients with DME who have achieved extended treatment intervals with newer anti-VEGF therapies, providing insights into patient selection for these therapies and determining the optimal treatment interval.

Target Audience

Retina Specialists

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Recognize relevant challenges in treatment adherence in patients with diabetic eye disease
Apply recently approved durable treatments for the management of DME and DR in appropriate patients

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is accredited by COPE to provide continuing education to optometrists.

Physicians’ Education Resource^®, LLC designates this activity for a maximum of 0.25 COPE credits.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

GET STARTED WITH THIS PROGRAM:

Related Content